DDX53 and neoplasm: All mice that originally had complete CT26 tumor regression continued to demonstrate durable protection from rechallenge with CT26 on day 85, although in the groups receiving the lowest doses (0.5 and 0.2 mg/kg), a small mass was measured that was quickly eliminated.